Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

优泌林 - NMPA Drug Approval Details

Approvals/NMPA/Recombinant Human Insulin Injection

Approved

生物制品

Recombinant Human Insulin Injection

LILLY FRANCE🇨🇳 National Medical Products Administration

Approval Date: Dec 16, 2021
Approval ID: 8DqcElY4Tau
Company: LILLY FRANCE
Type: 生物制品

Approval Details

Approval Id: 8DqcElY4Tau
Approval Number: 国药准字SJ20170013
Generic Name: 人胰岛素注射液
Generic Name En: Recombinant Human Insulin Injection
Trade Name: 优泌林
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 3ml:300单位（笔芯）
Reg Date: 2021-12-16
Expired Date: 2026-12-15
Company Name: LILLY FRANCE
Production Company Name: LILLY FRANCE
Company Detail Path: /organization/e411d213a21479c9/lilly-france
Production Company Detail Path: /organization/e411d213a21479c9/lilly-france

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 16, 2021

Approval ID

8DqcElY4Tau

Type

生物制品

Back to NMPA Approvals